Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide +/- Abiraterone Pre-op for High Risk Prostate Cancer
NCT03279250Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide, Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2017; status: completed.
02
Drugs
apalutamideAbiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03279250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279250.